Retinoblastoma Treatment Global Market Report 2025
상품코드:1825895
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
망막모세포종 치료 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%로 26억 5,000만 달러로 성장할 것입니다. 예측 기간의 성장은 안과 치료 및 수술에 대한 수요 증가, 망막모세포종 발생률 증가, 연구개발 활동 활성화, 망막모세포종 치료에 대한 인식 증가, 의료비 지출 증가에 기인합니다. 예측 기간 동안 주요 동향으로는 의료 기술 발전, 진단 능력 향상, 소아 종양학에 대한 투자 확대, 신제품 승인, 의료 인프라 개선 등을 꼽을 수 있습니다.
향후 5년간 5.3%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 이탈리아나 브라질에서 수입되는 동맥 내 화학요법용 카테터와 방사성 플라크의 비용을 상승시키고, 소아암 치료를 지연시키거나 종양학 비용을 상승시킬 수 있기 때문에 미국의 의료 공급망을 혼란에 빠뜨릴 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
안과 치료 및 수술에 대한 수요 증가가 당분간 망막모세포종 치료 시장 확대를 견인할 것으로 예상됩니다. 안과 치료 및 수술에는 눈과 시각계에 영향을 미치는 장애의 진단, 관리 및 교정을 목적으로 하는 다양한 의료 개입 및 시술이 포함됩니다. 이러한 수요 급증은 인구 고령화, 백내장 및 노화성 황반변성과 같은 질병의 유병률 증가, 보다 효율적이고 편리한 치료를 가능하게 하는 기술 발전, 조기 발견 및 조기 개입에 대한 인식의 증가 등의 요인에 기인합니다. 망막모세포종 치료는 안구 내 암의 증식을 억제하고 전이와 재발을 방지하는 동시에 시력과 안구 기능을 유지하기 위한 안과적 수술이 필수적입니다. 예를 들어, 2023년 9월 영국 건강 개선 및 격차 대책실의 보고서에 따르면, 영국의 백내장 수술 입원 환자 수는 409만 명을 넘어섰으며, 2022년까지 회계연도 인구 10만 명당 입원 환자 수는 3,803명(3,789명-3,816명)에 달했습니다. 또한, 같은 기간 동안 시행된 망막박리 수술 입원 건수는 1,900여 건, 유리체강내 주사치료 시행 건수는 67만 7,000여 건으로 인구 10만 명당 비율은 각각 23.4(22.9-24.0명), 4,796명(4,769-4,823명)으로 집계됐습니다. 그 결과, 안과 치료 및 수술에 대한 수요 증가가 망막모세포종 치료 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 망막모세포종 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 망막모세포종 치료 시장 : 성장률 분석
세계의 망막모세포종 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 망막모세포종 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 망막모세포종 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 망막모세포종 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비유전성 망막모세포종
유전성 망막모세포종
세계의 망막모세포종 치료 시장 : 치료 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
수술
방사선 치료
레이저 치료(광응고술)
냉동요법
온열요법
화학요법
눈동맥 주입 화학요법
고용량 화학요법과 줄기세포 이식
세계의 망막모세포종 치료 시장 질병 스테이지별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
안내 망막모세포종
안구외 망막모세포종
세계의 망막모세포종 치료 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
암 연구소
기타 용도
세계의 망막모세포종 치료 시장 : 하위 세분화 비유전성 망막모세포종(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
편측성 비유전성 망막모세포종
양측성 비유전성 망막모세포종
세계의 망막모세포종 치료 시장 : 하위 세분화 유전성 망막모세포종(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
양측성 유전성 망막모세포종
편측성 유전성 망막모세포종
제7장 지역별·국가별 분석
세계의 망막모세포종 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 망막모세포종 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
망막모세포종 치료 시장 : 경쟁 구도
망막모세포종 치료 시장 : 기업 개요
Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Novartis AG
Pfizer Inc.
GlaxoSmithKline Plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Baxter International Inc.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Otsuka Pharmaceutical
Daiichi Sankyo Company
Taiho Pharmaceutical Co. Ltd.
Icon Bioscience Inc.
Ono Pharmaceutical Co. Ltd.
Nippon Shinyaku Co. Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
망막모세포종 치료 시장 2029 : 새로운 기회를 제공하는 국가
망막모세포종 치료 시장 2029 : 새로운 기회를 제공하는 부문
망막모세포종 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Retinoblastoma treatment encompasses medical interventions and therapies directed at diagnosing, managing, and potentially curing retinoblastoma, a rare type of eye cancer predominantly found in young children, typically before the age of five. The primary objective of retinoblastoma treatment is to eliminate or control the cancerous growths within the eye(s) while preserving vision and minimizing the risk of metastasis or recurrence.
The main types of retinoblastoma treatment include non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma, a rare cancer affecting children under six years old, encompasses various treatment modalities such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy, and high-dose chemotherapy with stem cell transplant. These treatments are applicable to both intraocular and extraocular retinoblastoma stages and are commonly administered in hospitals, cancer institutes, and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The retinoblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides retinoblastoma treatment market statistics, including retinoblastoma treatment industry global market size, regional shares, competitors with a retinoblastoma treatment market share, detailed retinoblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. This retinoblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The retinoblastoma treatment market size has grown strongly in recent years. It will grow from $2.03 billion in 2024 to $2.15 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing number of funding, chance of recurrence of retinoblastoma, early diagnosis and treatment of retinoblastoma, growing awareness regarding different type of cancers, considerable growth in cancer research.
The retinoblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing demand for ophthalmic treatment and surgeries, increasing incidence of retinoblastoma, increasing research and development activities, growing awareness pertaining to retinoblastoma treatment, increasing healthcare expenditure. Major trends in the forecast period include advancements in medical technology, improved diagnostic capabilities, augmented investments in pediatric oncology, new product approval, improvements in medical infrastructure.
The forecast of 5.3% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for intra-arterial chemotherapy catheters and radioactive plaques imported from Italy and Brazil, potentially delaying pediatric cancer care and raising oncology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising need for ophthalmic treatment and surgeries is anticipated to drive the expansion of the retinoblastoma treatment market in the foreseeable future. Ophthalmic treatment and surgeries encompass a range of medical interventions and procedures aimed at diagnosing, managing, and correcting disorders affecting the eyes and visual system. This demand surge is attributed to factors such as an aging population, increased prevalence of conditions such as cataracts and age-related macular degeneration, technological advancements enabling more efficient and accessible treatments, and heightened awareness leading to earlier detection and intervention. Retinoblastoma treatment is essential for ophthalmic surgeries aimed at addressing cancerous growths within the eye(s), preventing metastasis or recurrence, while also preserving vision and eye function. For example, in September 2023, a report from the UK's Office for Health Improvement and Disparities revealed over 4.09 million admissions for cataract surgery in England, with a rate of 3,803 (3,789 to 3,816) per 100,000 population in the financial year ending 2022. Additionally, there were over 10,900 admissions for rhegmatogenous retinal detachment surgeries and over 677,000 intravitreal injection therapy procedures performed during the same period, with rates of 23.4 (22.9 to 24.0) and 4,796 (4,769 to 4,823) per 100,000 population, respectively. Consequently, the rising demand for ophthalmic treatment and surgeries is propelling the growth of the retinoblastoma treatment market.
Key players in the retinoblastoma treatment market are dedicated to developing innovative solutions, such as oncolytic adenovirus, to cater to the evolving needs of customers with enhanced functionalities. An oncolytic adenovirus is a genetically modified virus designed to infect and selectively destroy cancer cells while sparing normal cells. For instance, in February 2022, VCN Biosciences, a biotechnology company based in Spain, received orphan drug designation from the U.S. Food and Drug Administration for VCN-01, a genetically engineered oncolytic adenovirus intended for retinoblastoma treatment. VCN-01's distinctive feature lies in its oncolytic adenovirus nature, which is currently undergoing clinical trials targeting cancers with no definitive cure, including pancreatic carcinoma and retinoblastoma (RB). VCN-01 has undergone scrutiny in four phase 1 clinical trials and is being investigated as a standalone treatment option for RB patients who have previously undergone unsuccessful chemotherapy. Intravitreal administration of VCN-01 has demonstrated complete remission and tumor reduction in several patients, paving the way for its orphan drug status approval.
In March 2022, Synthetic Biologics Inc., a biotechnology company based in the United States, acquired VCN Biosciences S.L. for an undisclosed sum. This acquisition represents a significant advancement in Synthetic Biologics' pipeline, integrating VCN's primary clinical-stage drug candidate, VCN-01. VCN Biosciences S.L. is a biotechnology company based in Spain specializing in retinoblastoma treatment.
Major companies operating in the retinoblastoma treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co. Ltd., Icon Bioscience Inc., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Cadila Pharmaceuticals, Arcus Biosciences Inc., Sheba Medical Center, Cellceutix Corporation, Phio Pharmaceuticals Inc.
North America was the largest region in the retinoblastoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the retinoblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Retinoblastoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on retinoblastoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for retinoblastoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The retinoblastoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Non-Hereditary Retinoblastoma; Hereditary Retinoblastoma
3. Retinoblastoma Treatment Market Trends And Strategies
4. Retinoblastoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Retinoblastoma Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Retinoblastoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Retinoblastoma Treatment Market Growth Rate Analysis
5.4. Global Retinoblastoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Retinoblastoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Retinoblastoma Treatment Total Addressable Market (TAM)
6. Retinoblastoma Treatment Market Segmentation
6.1. Global Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Hereditary Retinoblastoma
Hereditary Retinoblastoma
6.2. Global Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Radiation Therapy
Laser Therapy (Photocoagulation)
Cryotherapy
Thermotherapy
Chemotherapy
Ophthalmic Artery Infusion Chemotherapy
High-Dose Chemotherapy And Stem Cell Transplant
6.3. Global Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intraocular Retinoblastoma
Extraocular Retinoblastoma
6.4. Global Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Institutes
Other Applications
6.5. Global Retinoblastoma Treatment Market, Sub-Segmentation Of Non-Hereditary Retinoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Unilateral Non-Hereditary Retinoblastoma
Bilateral Non-Hereditary Retinoblastoma
6.6. Global Retinoblastoma Treatment Market, Sub-Segmentation Of Hereditary Retinoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bilateral Hereditary Retinoblastoma
Unilateral Hereditary Retinoblastoma
7. Retinoblastoma Treatment Market Regional And Country Analysis
7.1. Global Retinoblastoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Retinoblastoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
